Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

The state of Utah is suing Snapchat over features it says are designed to addict children, while potentially exposing them to illegal drug sales, predatory adults and an artificial intelligence ...

A civilian contract tutor for incarcerated youth has been charged with multiple felonies for allegedly working with a teenage ward to smuggle Xanax into Los Padrinos Juvenile Hall in Downey, while the ...

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

A cause of death has been revealed in the passing of 28-year-old adult film star Kylie Page, who passed away in her Los ...

The last two years have seen some newly enacted state policies cast aside in short order, followed by a reversion to more ...

Substance use was implicated in more than half of all adult drownings in baths or hot tubs in the last 10 years, according to ...

To report elder or dependent-adult abuse in a skilled-nursing, rehab facility or hospital, call the Department of Public Health at 530-895-6711 and/or the Long-Term-Care Ombudsman at 530-898-6628.

As young adults seek truth, the Church's focus on tradition and community fosters a renewal, welcoming thousands into a shared spiritual journey. MENAFN20062025007421016031ID1109702532 ...

News GlobeNewswire Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE) ...

Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA's long-standing accelerated approval program generally issues ...

Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, is currently being studied for safety and efficacy in two ongoing open label multicenter Phase 1/2 trials: NCT05135091 ...